Orphan Drug Commercialization with solid potential to treat uncommon sicknesses may not be appropriate for commercialization. The turn of events and endorsement cycle might be excessively extended and costly. Setting up a geologically scattered and exceptionally complex store network may not be possible, and executing the required postmarketing clinical investigations might be extremely challenging. Drug […]
